129 drug price reduction starting in October

PVA

The NHIS has completed negotiations. The MOHW will push for drug price adjustment on the 1st of next month

Price of Chungkundang Gliatirin will be reduced by 0.2%

It also includes seven items of Choline alfoscerate

Drugs that sell a lot or have a high price range will be lowered as of the 1st of next month.

 

It will be reduced by up to 10%.

 

It also included seven Choline alfoscerates that negotiated the redemption of drug costs for clinical revaluation.

 

AstraZeneca's Lynparza 50mg, Kadcyla 100mg, and Kadcyla 160mg succeeded in risk-sharing contracts (RSA), respectively, with drug prices cut from 1% to 9%.

 

According to the industry, it will be applied as of October 1 if the revision is finalized soon.

 

This drug price cut corresponds to the type 'Na' and 'Da' of the Price-Volume Agreement.

 

First of all, the type 'Na'' is a new drug which price has not been adjusted according to type 'Ka' and four years have passed since the date of registration, and the total amount of claims for the same product group has increased by more than 30%.

 

Among them, the NHIS negotiates with the company if the amount of ▲ claims has increased by more than 60% from the previous year's claim, or if the amount of ▲ claims increases by more than 10% and the increase is more than 5 billion won.

 

The type 'Na' drug, which will be applied as of the 1st of next month, is Bayer Korea's Eilea, which has been decided to cut 2.5% in the negotiations.

 

There are as many as 128 items.

 

In particular, some of the Price-Volume Agreement drugs include recently completed Choline alfoscerate negotiations.

 

A total of three drugs have succeeded in renegotiating RSA and will be maintained at a reduced price next month.

 

AstraZeneca's Lynparza 50mg will fall 9.1% from the existing drug price, while Kadcyla 100mg and Kadcyla 160mg by Roche will be reduced by 1.7%, respectively.